Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis

Objectives
Investigate if the recommendations by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) to provincial, territorial and federal drug plans about whether to list non-oncology and oncology drug-indication combinations on their formularies are associated with whether the drug-indication combination was approved via the standard evidence pathway or the Notice of Compliance with conditions (NOC/c – limited evidence) pathway.
Design
Cohort study.
Data sources
Web sites of the CDR and pCODR up to the end of March 31, 2017; journal articles evaluating drugs approved through the NOC/c pathway, the Notice of Compliance database, the Notice of Compliance with conditions web site and the Summary Basis of Decision website.
Interventions
Recommendations by the CDR and pCODR.
Primary and secondary outcome measures
Analysis of the percent of drugs receiving positive listing recommendations from CDR and pCODR depending on the pathway used to approve the d...